Great News|Anling Biomed (Suzhou) Successfully Gains Extending GLP Accreditation from NMPA
Date 2023-02-16 16:19
Author：admin
Recently, Anling Biomed (Suzhou) Co., Ltd (Anling (Suzhou))—wholly-owned subsidiaries of ZSHK Laboratories Limited (ZSHK) has been awarded GLP accreditation (Registration Number: GLP23002157) issued by the National Medical Products Administration (NMPA) for the projects of reproductive toxicity test (stage I, II (rodents) and III) and carcinogenicity test. This signifies that the drug evaluation center operated by Anling (Suzhou) has come across NMPA’s strict on-site inspection and has fulfilled GLP requirements regarding the organization and management of staff, equipment, experimental materials, standard operating procedures and experiment operation, successfully passed the national GLP accreditation.
ZSHK has established pre-clinical GLP platforms, including Anling Biomed (Suzhou) Co. Ltd. and Anling Biomed (Shenzhen) Co. Ltd. Possessing primate breeding facility and dog breeding facility at the same time, ZSHK is able to provide high-quality experimental non-human primates and dogs having clear and complete genealogy records and high-end animal models; and is able to undertake new drug evaluation projects that fulfils national and international standards including drug efficacy screening, drug efficacy testing, metabolic study and safety evaluation etc. Major client of the company are new drug R&D enterprises, generic drugs production enterprises and chemical R&D and production enterprises, offering pre-clinical research and technical support involving chemical drugs, biological drugs, Chinese medicine, medical devices, cell therapy products and chemical area.
